-
1.发明申请HORMONE AND DRUG CONCENTRATIONS IN THE PORTAL VEIN AND HEPATIC SINUSOIDS 审中-公开门静脉和静脉麻醉药物中的HORMONE和DRUG浓度公开(公告)号：US20080120039A1
公开(公告)日：2008-05-22
申请号：US11618383
申请日：2006-12-29
申请人： Kevin Hall , David Polidori , Scott Siler
发明人： Kevin Hall , David Polidori , Scott Siler
CPC分类号： G01N33/74 , G06F19/3468 , G16H50/50
摘要： The invention relates to novel methods of informing a medical decision by determining a hormone or drug concentration in a portal vein or hepatic sinusoid of a mammal. The invention also relates to methods of determining hormone or drug concentration in the portal vein or hepatic sinusoids. Further the invention relates to methods of utilizing these concentrations to calculate infusion rates for hormone or drugs in order to achieve a desired portal vein or hepatic sinusoid concentration of such a hormone or drug.
摘要翻译： 本发明涉及通过确定哺乳动物门静脉或肝窦状体中的激素或药物浓度来通知医学决定的新方法。 本发明还涉及确定门静脉或肝窦腔内激素或药物浓度的方法。 此外，本发明涉及利用这些浓度来计算激素或药物的输注速率以达到期望的门静脉或这种激素或药物的肝窦状液浓度的方法。
-
公开(公告)号：US20070026458A1
公开(公告)日：2007-02-01
申请号：US11303754
申请日：2005-12-16
申请人： David Polidori , Scott Siler , Leif Wennerberg , Seth Michelson , Michael Reed
发明人： David Polidori , Scott Siler , Leif Wennerberg , Seth Michelson , Michael Reed
CPC分类号： G01N33/66 , G01N33/6893 , G01N33/723 , G01N2333/62 , G01N2800/042 , G01N2800/52
摘要： The invention encompasses novel biomarkers and methods for assessing insulin resistance in a subject. The novel biomarkers of the invention include various plasma constituent (e.g., insulin, glucose, lactate and/or triglyceride) concentrations. The methods of the invention include measuring various plasma constituent concentrations and calculating a predicted euglycemic hyperinsulinemic clamp glucose infusion rate (GIR) based on the plasma constituent concentrations.
摘要翻译： 本发明包括用于评估受试者中胰岛素抵抗的新型生物标志物和方法。 本发明的新型生物标志物包括各种血浆成分（例如胰岛素，葡萄糖，乳酸和/或甘油三酸酯）浓度。 本发明的方法包括测量各种血浆成分浓度，并基于血浆成分浓度计算预测的正血糖高胰岛素钳位葡萄糖输注速率（GIR）。
-
公开(公告)号：US20070032420A1
公开(公告)日：2007-02-08
申请号：US11352455
申请日：2006-02-09
申请人： David Polidori , Scott Siler
发明人： David Polidori , Scott Siler
CPC分类号： A61K31/155 , A61K31/201 , A61K31/444 , A61K38/04 , A61K38/30 , A61K45/06 , A61K2300/00
摘要： In general this invention can be viewed as encompassing novel methods of treating diabetes and insulin resistance. The inventors have made the discovery that increasing secretion of endogenous glucagon-like peptide-1 (GLP-1) in combination with inhibiting the activity of dipeptidyl peptidase I (DPP-IV) can have a significant impact on hyperglycemia and insulin secretion in subjects suffering from diabetes and/or insulin resistance. Further the invention encompasses methods of identifying subjects having elevated secretion of GLP-1, methods of assessing sensitivity to a GLP-1 secretagogue, and methods of treating diabetes in these subjects by administering a GLP-1 secretagogue to alleviate at least one symptom of diabetes.
摘要翻译： 通常，本发明可以被看作是包括治疗糖尿病和胰岛素抵抗的新颖方法。 发明人已经发现内源性胰高血糖素样肽-1（GLP-1）的分泌与抑制二肽基肽酶I（DPP-IV）的活性的组合的增加可以对受试者的高血糖和胰岛素分泌具有显着影响 来自糖尿病和/或胰岛素抵抗。 此外，本发明包括鉴定GLP-1分泌增加的受试者的方法，GLP-1促分泌素的敏感性评估方法以及通过施用GLP-1促分泌素来减轻糖尿病至少一种症状的这些受试者的糖尿病治疗方法 。
-
公开(公告)号：US20070071681A1
公开(公告)日：2007-03-29
申请号：US11377614
申请日：2006-03-15
申请人： Kapil Gadkar , Huub Kreuwel , Thomas Paterson , David Polidori , Saroja Ramanujan , Lisl Katharine Mie Shoda , Chan Whiting , Daniel Young , Yanan Zheng
发明人： Kapil Gadkar , Huub Kreuwel , Thomas Paterson , David Polidori , Saroja Ramanujan , Lisl Katharine Mie Shoda , Chan Whiting , Daniel Young , Yanan Zheng
CPC分类号： G16H50/50 , G01N2800/042 , G06Q50/24 , G16B5/00 , G16B20/00
摘要： The invention encompasses novel methods for developing a computer model of type 1 diabetes in a mammal. In particular, the models can include representations of biological processes associated with a pancreatic lymph node and one or more pancreatic islets. Alternatively, the models can include representations of biological processes associated with at least two conditions selected from the group consisting of autoreactive T cell production, autoreactive T cell priming, insulitis and hyperglycemia. The invention also provides methods for developing a computer model of a non-insulin replacement treatment of type 1 diabetes. The invention also encompasses computer models of type 1 diabetes, methods of simulating type 1 diabetes and computer systems for simulating type 1 diabetes and the uses thereof.
摘要翻译： 本发明包括用于开发哺乳动物中1型糖尿病计算机模型的新方法。 特别地，模型可以包括与胰腺淋巴结和一个或多个胰岛相关联的生物过程的表示。 或者，模型可以包括与选自自身反应性T细胞产生，自身反应性T细胞引发，胰岛炎和高血糖的至少两种病症相关的生物学过程的表示。 本发明还提供了开发1型糖尿病非胰岛素替代治疗计算机模型的方法。 本发明还包括1型糖尿病的计算机模型，模拟1型糖尿病的方法和用于模拟1型糖尿病的计算机系统及其用途。
-
公开(公告)号：US07654955B2
公开(公告)日：2010-02-02
申请号：US10995030
申请日：2004-11-19
申请人： David Polidori , Kevin Hall
发明人： David Polidori , Kevin Hall
IPC分类号： A61B5/00
摘要： Apparatus and methods for assessing metabolic substrate utilization are described. In one embodiment, a processor-readable medium includes code to receive data indicative of a plasma glucose concentration, a plasma free fatty acid concentration, and a respiratory quotient of a subject. The processor-readable medium also includes code to calculate, based on the data, respective values of a set of metabolic parameters. The set of metabolic parameters includes a first metabolic parameter and a second metabolic parameter. The value of the first metabolic parameter is indicative of whether the subject has a predisposition towards oxidation of a first type of metabolic substrate or a second type of metabolic substrate, and the value of the second metabolic parameter is indicative of the subject's responsiveness to a change in availability of the first type of metabolic substrate or the second type of metabolic substrate.
摘要翻译： 描述了用于评估代谢底物利用的装置和方法。 在一个实施例中，处理器可读介质包括接收指示受试者血浆葡萄糖浓度，血浆游离脂肪酸浓度和呼吸商的数据的代码。 处理器可读介质还包括用于基于数据计算一组代谢参数的相应值的代码。 该组代谢参数包括第一代谢参数和第二代谢参数。 第一代谢参数的值指示受试者是否具有倾向于第一类型的代谢底物或第二类型的代谢底物的氧化，并且第二代谢参数的值表示受试者对变化的反应性 在第一类代谢底物或第二类代谢底物的可用性方面。
-
公开(公告)号：US20070026365A1
公开(公告)日：2007-02-01
申请号：US11346990
申请日：2006-02-03
申请人： Christina Friedrich , Anuraag Kansal , David Klinke , Seth Michelson , Thomas Paterson , David Polidori , Jeff Trimmer , Leif Wennerberg
发明人： Christina Friedrich , Anuraag Kansal , David Klinke , Seth Michelson , Thomas Paterson , David Polidori , Jeff Trimmer , Leif Wennerberg
IPC分类号： G09B19/00
CPC分类号： G06Q50/22 , G06F19/324 , G16B5/00 , G16H10/20
摘要： The invention encompasses methods, including computer-implemented methods, of defining a virtual patient population and mapping the virtual patient population to a population of real patients. The invention utilizes virtual measures from one or more virtual patients, and data representative of multiple real subjects in a sample population, such as data collected from patients in a clinical trial or epidemiological study of a real population. The invention includes evaluating the similarity between the virtual patients and the real subjects, and assigning prevalences to the virtual patients based on the evaluation. The similarity can be assessed using some or all of the virtual measures of the virtual patients and some or all of the data obtained for the real subjects. Any of various goodness-of-fit measures can be used to evaluate the similarity or to help identify prevalences. The virtual patient population is defined as the virtual patients according to their respective prevalences.
摘要翻译： 本发明涵盖包括计算机实现的方法，定义虚拟患者人群并将虚拟患者人群映射到真实病人群体的方法。 本发明利用来自一个或多个虚拟患者的虚拟测量，以及代表样本群体中的多个实际受试者的数据，例如在临床试验或对真实人群的流行病学研究中从患者收集的数据。 本发明包括评估虚拟患者与实际受试者之间的相似性，并根据评估将流行率分配给虚拟患者。 可以使用虚拟患者的一些或全部虚拟测量以及为真实对象获得的部分或全部数据来评估相似性。 可以使用任何适合度的措施来评估相似性或帮助确定流行率。 虚拟患者群体根据各自的流行率定义为虚拟患者。
-
公开(公告)号：US20050197785A1
公开(公告)日：2005-09-08
申请号：US10995030
申请日：2004-11-19
申请人： David Polidori , Kevin Hall
发明人： David Polidori , Kevin Hall
摘要： Apparatus and methods for assessing metabolic substrate utilization are described. In one embodiment, a processor-readable medium includes code to receive data indicative of a plasma glucose concentration, a plasma free fatty acid concentration, and a respiratory quotient of a subject. The processor-readable medium also includes code to calculate, based on the data, respective values of a set of metabolic parameters. The set of metabolic parameters includes a first metabolic parameter and a second metabolic parameter. The value of the first metabolic parameter is indicative of whether the subject has a predisposition towards oxidation of a first type of metabolic substrate or a second type of metabolic substrate, and the value of the second metabolic parameter is indicative of the subject's responsiveness to a change in availability of the first type of metabolic substrate or the second type of metabolic substrate.
摘要翻译： 描述了用于评估代谢底物利用的装置和方法。 在一个实施例中，处理器可读介质包括接收指示受试者血浆葡萄糖浓度，血浆游离脂肪酸浓度和呼吸商的数据的代码。 处理器可读介质还包括用于基于数据计算一组代谢参数的相应值的代码。 该组代谢参数包括第一代谢参数和第二代谢参数。 第一代谢参数的值指示受试者是否具有倾向于第一类型的代谢底物或第二类型的代谢底物的氧化，并且第二代谢参数的值表示受试者对变化的反应性 在第一类代谢底物或第二类代谢底物的可用性方面。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.017 秒)